Antibiotic Inhalers Galore (Part 1):  More Combinations and Permutations than a Rubik’s Cube

There is much interest in inhaled antibiotics these days.  Prima facie, the logic for this approach is compelling: Getting the antibiotic (and a lot of it) directly to the site of infection, while avoiding systemic toxicity, sounds like optimized efficacy Continue reading Antibiotic Inhalers Galore (Part 1):  More Combinations and Permutations than a Rubik’s Cube

Plazomicin – A Quick Take On A Complex Drug With A Complex Development Path

Whenever a new drug is in late stage development, its prospects become the focus of intense scrutiny. Plazomicin (ACHN-490), like any Phase 3 drug should be evaluated along the following dimensions: Differentiation: within its class & compared to competitors: Does it Continue reading Plazomicin – A Quick Take On A Complex Drug With A Complex Development Path

No Easy Day: Dose Calculations for Aminoglycosides and Vancomycin

Searching data on antibiotic use in surgery prophylaxis, I came across an article from the Mayo Clinic [1].  The authors mention that approx. 75% of patients that developed surgical site infections did not get proper antibiotic prophylaxis.  Errors were made in (1) Continue reading No Easy Day: Dose Calculations for Aminoglycosides and Vancomycin

Aerosolized Antibiotics & Selling Nebulizers

“The medicine comes for free, just pay us for the inhaler” should be the marketing slogan for this group of therapeutics.  Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to ‘evergreen’ off-patent Continue reading Aerosolized Antibiotics & Selling Nebulizers